March 2020 Legislative & Regulatory Briefing: Articles include CMS Issues Contract Year 2021 and 2022 Medicare Advantage and Part D Proposed Rule; AMCP Shares CMS Resources for COVID-19 Response; AMCP Submits Comments on Drug Importation on Proposals
April 2020 AMCP News & Views: Read articles on AMCP Amicus Brief in Rutledge v. PCMA Warns Against a Ruling That Diminishes Use of Managed Care Pharmacy Tools; AMCP Launches Daily Dose: COVID-19 Weekly Edition; and more
March 2020 AMCP News & Views: Read articles on AMCP Leaders Discuss Strategic Plan, Priorities, Foundation, JMCP, and More; AMCP Seeks Member Input on CMS Proposals; and more
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its proposed rule, “Medicare and Medicaid Programs; Contract Year 2021 and 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly” published on February 18, 2020.
Headache is one of the most common symptoms in the general population, but despite its high prevalence and impairment, migraine is often not recognized or effectively treated. To understand the appropriate and cost-effective use of novel treatments for migraine headaches, AMCP convened an expert forum of stakeholders.
Our community is extremely grateful the Administration and Congress took swift action to help businesses, nonprofits and millions of Americans withstand the coronavirus pandemic, which jeopardizes our collective livelihood, welfare and safety. Provisions within the Coronavirus Aid, Relief and Economic Security (CARES) Act will prove vital to help stabilize our economy and keep Americans safe.
AMCP urges justices to affirm federal ERISA law to ensure managed care pharmacy practices continue helping patients access medicines at affordable costs.
